Ann: MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRA, page-5

re: Ann: MESOBLAST PROVIDES UPDATE ON CLINICA... Ladenburg Thalmann's view on the Prochymal update.

Kevin DeGeeter, Ladenburg Thalmann (4/29/14) "Mesoblast Ltd. expects to meet with the U.S. Food and Drug Administration (FDA) 'shortly' to discuss plans to submit a biologic license application based on existing clinical data, including data from an expanded access program. . .in our view, an update on the program is likely in June 2014 following distribution of written minutes from the FDA meeting. . .we reiterate our Buy rating with a $52 price target."
http://www.thelifesciencesreport.com/pub/co/4251

Note:the current (MBLTY) -Other OTC SP is US$22.30

+13 job applications and 2 recent major league appointments (in Pharma industry).


Please DYOR and Good luck to all.